Lena Kranz

Lena Kranz

Company: BioNTech

Job title: Director Cancer Vaccines


Rna-Encoded, Extended Half-Life Cytokines In Combination With Rna Vaccination For Synergistic Anti-Tumor Activity 1:45 pm

• Optimized mRNA platform using lipid nanoparticle technology providing superior immunogenicity • Proof of concept in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT) targeting nonmutated, shared tumor-associated antigens • Combination with RNA-encoded, extended half-life cytokines for T cell modulation and enhanced anti-tumor activityRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.